Biotech entity
fda-approval is the sole category represented across all 1 tracked stories. Of the tracked stories, 1 of 1 also mention COVID-19 Vaccine, the most common co-covered peer. The tracked stories average 2 original sources each. Respiratory Syncytial Virus (RSV) vaccine appears in 1 tracked Biotech story from July 21, 2026.
Last mentioned: Jul 21, 2026
Entity pulse
Coverage balance Positive coverage leads. Positive coverage exceeds negative coverage by 100 percentage points.
Figures are computed live from our source-verified story record — see our methodology for how impact and sentiment are derived.
fda-approval is the sole category represented across all 1 tracked stories. Of the tracked stories, 1 of 1 also mention COVID-19 Vaccine, the most common co-covered peer. The tracked stories average 2 original sources each. Respiratory Syncytial Virus (RSV) vaccine appears in 1 tracked Biotech story from July 21, 2026.
Computed from the 1 stories linked to this entity, with beat comparisons drawn from all 10 Biotech stories published in the same date window. Shares are omitted below five stories and comparisons below a twenty-story baseline.
Coverage cohort
Other entities that clear the same relevance threshold in stories also covering Respiratory Syncytial Virus (RSV) vaccine. Shared-story counts are live from our verified record — not editorial picks.
Cramer Endorsement & 109% YTD Gain
Motley Fool highlights 109% year-to-date surge and Jim Cramer's comment that Moderna is 'finally investable again'.
Quarterly Update
Moderna reports a 26% reduction in operating expenses, reiterates up to 10% revenue growth target for 2026.
Post-Pandemic Decline
Demand for COVID vaccines wanes, RSV sales miss expectations, and CMV candidate fails; stock loses over 80% from peak.
COVID Vaccine Success
Moderna's COVID-19 vaccine drives record revenue; stock surges over 2,000% from early 2020 through August 2021.
Moderna’s cost cuts and pipeline milestones, from RSV commercialization to latent virus programs, are restoring biotech investor confidence despite past setbacks.
Source: Adria Cimino (us) · fool.com
Respiratory Syncytial Virus (RSV) vaccine is linked from 1 story on this site, each scored at or above our 35% relevance threshold — see how these pages are built.
See something wrong on this page — a misattributed entity, a wrong stat, a broken source link? Report a data issue.
